When to Resume Eltrombopag in Aplastic Anemia
Resume eltrombopag when platelet counts fall below 30 × 10⁹/L or below 50 × 10⁹/L if bleeding occurs, and restart at the minimum effective dose that previously triggered a response 1.
Specific Resumption Criteria
For High Platelet Counts
While the provided evidence focuses primarily on immune thrombocytopenia (ITP) rather than aplastic anemia, the principles of TPO-RA management suggest:
- Monitor platelet counts closely during treatment
- Hold eltrombopag temporarily if excessive thrombocytosis develops
- Resume at a reduced dose once platelet counts normalize to safe therapeutic ranges
For Elevated Liver Enzymes
The FDA label and clinical practice indicate 2:
- Hold eltrombopag if significant hepatotoxicity develops
- Resume only after liver enzymes improve to acceptable levels
- Consider dose reduction upon restart
- Monitor liver function tests closely after resumption
Evidence-Based Resumption Strategy
Timing of Restart
Based on aplastic anemia-specific data 2:
- Eltrombopag can be safely restarted after treatment interruption
- In the pivotal aplastic anemia trial, patients who achieved multi-lineage responses were able to discontinue eltrombopag and later restart it successfully when needed
- 4 of 8 patients who achieved robust responses discontinued treatment and maintained responses for a median of 8.1 months (range 7.2-10.6 months) 2
Dosing Upon Restart
Start at 50 mg once daily (the standard initial dose for aplastic anemia) and escalate as needed 2:
- Increase in 2-week intervals based on platelet response
- Maximum dose: 150 mg once daily
- For patients of East Asian descent, consider starting at 25 mg once daily due to higher drug exposure 3
Key Clinical Considerations
Response Kinetics After Restart
- Hematologic responses typically occur within 1-2 months of restarting eltrombopag 4
- Some patients may require up to 24 weeks for optimal response 5
- Multi-lineage responses can develop with continued treatment, even in patients who initially showed single-lineage improvement 6
Safety Monitoring After Resumption
Monitor the following closely:
- Liver function tests at baseline and regularly during treatment (eltrombopag carries hepatotoxicity risk) 2
- Complete blood counts weekly initially, then adjust frequency based on response
- Cytogenetic evaluation periodically, as clonal evolution can occur (19% of patients in long-term follow-up) 5
Important Caveats
Clonal evolution risk: In the combined analysis of 83 patients with refractory severe aplastic anemia, 16 (19%) developed cytogenetic abnormalities, most within 6 months of eltrombopag initiation 5. This temporal relationship suggests eltrombopag may promote expansion of pre-existing clones, though it does not appear to create new mutations.
Alternative TPO-RA: If eltrombopag was discontinued due to intolerance (particularly hepatotoxicity), consider switching to avatrombopag rather than restarting eltrombopag, as avatrombopag does not undergo significant hepatic metabolism and has demonstrated efficacy in eltrombopag-intolerant patients 4.
Duration of Retreatment
- Continue eltrombopag until robust hematologic response is achieved
- Some patients may require long-term or indefinite treatment
- Others may achieve sustained responses off-drug after 9-37 months of treatment 6
- Monitor for at least 12-24 months to assess durability of response
Practical Algorithm
Identify reason for interruption:
- High platelets → Resume when platelets normalize
- Elevated LFTs → Resume only after normalization and careful risk-benefit assessment
- Other toxicity → Address underlying cause before restart
Restart dosing:
- Begin at 50 mg daily (25 mg for East Asians)
- Escalate every 2 weeks based on response
- Maximum 150 mg daily
Monitor response:
- CBC weekly × 4 weeks, then biweekly
- LFTs at baseline, 2 weeks, then monthly
- Assess hematologic response at 3 months minimum
Adjust management:
- Continue if responding
- Consider discontinuation if robust normalization achieved
- Switch to alternative TPO-RA if intolerance recurs